Jos Jonkers
Hoogleraar Moleculaire experimentele oncogenetica en kankertherapieën
- Naam
- Prof.dr.ir. J.M.M. Jonkers Ph.D.
- Telefoon
- +31 71 527 2727
- j.m.m.jonkers@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0002-9264-9792
Hoogleraar Moleculaire experimentele oncogenetica en kankertherapieën
- Wiskunde en Natuurwetenschappen
- Leiden Academic Centre for Drug Research
- LACDR/Toxicology
- Ratz L., Brambillasca C.S., Bartke L., Huetzen M.A., Goergens J., Leidecker O., Jachimowicz R.D., Ven M. van de, Proost N., Siteur B., Korte-Grimmerink R. de, Bouwman R.J.P., Pulver E.M., Bruijn R. de, Isensee J., Hucho T., Pandey G., Lohuizen M., Mallmann P., Reinhardt H.C., Jonkers J.M.M. & Puppe J. (2022), Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer, Breast Cancer Research 24(1): 41.
- Bouwman R.J.P., Heijden I. van der, Gulden H. van der, Bruijn R. de, Braspenning M.E., Moghadasi S., Wessels L.F.A., Vreeswijk M.P.G. & Jonkers J.M.M. (2022), Correction: Functional categorization of BRCA1 variants of uncertain clinical significance in homologous recombination repair complementation assays (vol 26, pg 4559, 2020), Clinical Cancer Research 28(20): 4588.
- Pantelidou C., Sonzogni O., De Oliveria Taveira M., Mehta A.K., Kothari A., Wang D., Visal T., Li M.K., Pinto J., Castrillon J.A., Cheney E.M., Bouwman R.J.P., Jonkers J., Rottenberg S., Guerriero J.L., Wulf G.M. & Shapiro G.I. (2019), T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer, Cancer Discovery 9(6): 722-737.
- Drost R., Dhillon K.K., Gulden H. van der, Heijden I. van der, Brandsma I., Cruz C., Chondronasiou D., Castroviejo-Bermejo M., Boon U., Schut E., Burg E.van der, Wientjens E., Pieterse M., Klijn C., Klarenbeek S., Loayza-Puch F., Elkon R., Van Deemter L., Rottenberg S., Ven van de, M., Dekkers D.H., Demmers J.A., Gent D.C. van, Agami R., Balmaña J., Serra V., Taniguchi T., Bouwman R.J.P. & Jonkers J. (2016), BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1, Journal of Clinical Investigation 126(8): 2903-2918.
- Miltenburg M.H. van, Nimwegen M.J. van, Tijdens R.B., Lalai R.A., Kuiper R., Klarenbeek S., Schouten P.C., Vries A. de, Jonkers J.M.M. & Water B. van de (2014), Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation, British Journal of Cancer 110(11): 2747-2755.
- Gu Y., Bouwman R.J.P., Greco D., Saarela J., Yadav B., Jonkers J. & Kuznetsov S.G. (2014), Suppression of BRCA1 sensitizes cells to proteasome inhibitors, Cell Death and Disease 5: e1580.
- Bouwman P., Gulden H. van der, Heijden I. van der, Drost R., Klijn C.N., Prasetyanti P., Pieterse M., Wientjens E., Seibler J., Hogervorst F.B. & Jonkers J. (2013), A high-throughput functional complementation assay for classification of BRCA1 missense variants, Cancer Discovery 3(10): 1142-1155.
- Gorrini C., Baniasadi P.S., Harris I.S., Silvester J., Inoue S., Snow B., Joshi P.A., Wakeham A., Molyneux S.D., Martin B., Bouwman P., Cescon D.W., Elia A.J., Winterton-Perks Z., Cruickshank J., Brenner D., Tseng A., Musgrave M., Berman H.K., Khokha R., Jonkers J., Mak T.W. & Gauthier M.L. (2013), BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival, The Journal of Experimental Medicine 210(8): 1529-1544.
- Carlos A.R., Escandell J.M., Kotsantis P., Suwaki N., Bouwman P., Badie S., Folio C., Benitez J., Gomez-Lopez G., Pisano D.G., Jonkers J. & Tarsounas M. (2013), ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets, Nature Communications 4: 2697.
- Sotiropoulou P.A., Karambelas A.E., Debaugnies M., Candi A., Bouwman P., Moers V., Revenco T., Rocha A.S., Sekiguchi K., Jonkers J. & Blanpain C. (2013), BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny, Genes & Development 27(1): 39-51.
- Bowman-Colin C., Xia B., Bunting S., Klijn C., Drost R., Bouwman P., Fineman L., Chen X., Culhane A.C., Cai H., Rodig S.J., Bronson R.T., Jonkers J., Nussenzweig A., Kanellopoulou C. & Livingston D.M. (2013), Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer, Proceedings of the National Academy of Sciences 110(21): 8632-8637.
- Drost R., Bouwman R.J.P., Rottenberg S., Boon U., Schut E., Klarenbeek S., Klijn C., Van der Heijden I., Van der Gulden H., Wientjens E., Pieterse M., Catteau A., Green P., Solomon E., Morris J.R. & Jonkers J. (2011), BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance, Cancer Cell 20(6): 797-809.
- Evers B., Schut E., Van der Burg E., Braumuller T.M., Egan D.A., Holstege H., Edser P., Adams D.J., Wade-Martins R., Bouwman P. & Jonkers J. (2010), A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors, Clinical Cancer Research 16(1): 99-108.
- Badie S., Escandell J.M., Bouwman P., Carlos A.R., Thanasoula M., Gallardo M.M., Suram A., Jaco I., Benitez J., Herbig U., Blasco M.A., Jonkers J. & Tarsounas M. (2010), BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping, Nature Structural and Molecular Biology 17(12): 1461-1469.
- Boesten L.S.M., Zadelaar A.S.M., Nieuwkoop A. van, Hu L, Jonkers J, Water B. van de, Gijbels M.J.J., Made I. van der, Winther M.P.J. de, Havekes L.M. & Vlijmen B.J.M. van (2006), Macrophage retinoblastoma deficiency leads to enhanced atherosclerosis development in ApoE-deficient mice, The FASEB Journal 20(7): 953-955.